Point of care molecular and antigen detection tests for COVID-19: current status and future prospects

被引:6
作者
Stokes, William [1 ,2 ]
Berenger, Byron M. [1 ,3 ]
Venner, Allison A. [1 ,3 ]
Deslandes, Vincent [4 ,5 ,6 ]
Shaw, Julie L., V [4 ,5 ,6 ]
机构
[1] Alberta Precis Labs, Calgary, AB, Canada
[2] Univ Alberta, Dept Pathol & Lab Med, Edmonton, AB, Canada
[3] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada
[4] Eastern Ontario Reg Labs Assoc, Ottawa, ON, Canada
[5] Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada
[6] Univ Ottawa, Dept Pathol & Lab Med, Ottawa, ON, Canada
关键词
SARS-CoV-2; POCT; rapid antigen test; COVID-19; laboratory oversight; quality assurance; CANADIAN SOCIETY; RAPID ANTIGEN; NUCLEOCAPSID PROTEIN; SARS-COV-2; MANAGEMENT;
D O I
10.1080/14737159.2022.2122712
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Introduction Detection of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has been critical to support and management of the COVID-19 pandemic. Point of care testing (POCT) for SARS-CoV-2 has been a widely used tool for detection of SARS-CoV-2. Areas covered POCT nucleic acid amplification tests (NAATs) and rapid antigen tests (RATs) have been the most readily used POCT for SARS-CoV-2. Here, current knowledge on the utility of POCT NAATs and RATs for SARS-CoV-2 are reviewed and discussed alongside aspects of quality assurance factors that must be considered for successful and safe implementation of POCT. Expert opinion Use cases for implementation of POCT must be evidence based, regardless of the test used. A quality assurance framework must be in place to ensure accuracy and safety of POCT.
引用
收藏
页码:797 / 809
页数:13
相关论文
共 107 条
  • [1] Adamson B., 2022, MEDRXIV
  • [2] Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres
    Albert, Eliseo
    Torres, Ignacio
    Bueno, Felipe
    Huntley, Dixie
    Molla, Estefania
    Angel Fernandez-Fuentes, Miguel
    Martinez, Mireia
    Poujois, Sandrine
    Forque, Lorena
    Valdivia, Arantxa
    Solano de la Asuncion, Carlos
    Ferrer, Josep
    Colomina, Javier
    Navarro, David
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (03) : 472.e7 - 472.e10
  • [3] [Anonymous], CDC GUIDANCE SARS CO
  • [4] [Anonymous], EXPERT REV MOL DIAGN
  • [5] [Anonymous], 2020, PRELIMINARY REPORT J
  • [6] [Anonymous], 2021, SARS COV 2 REFERENCE
  • [7] Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines
    Araf, Yusha
    Akter, Fariya
    Tang, Yan-dong
    Fatemi, Rabeya
    Parvez, Md Sorwer Alam
    Zheng, Chunfu
    Hossain, Md Golzar
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 1825 - 1832
  • [8] Assessment of inactivation procedures for SARS-CoV-2
    Auerswald, Heidi
    Yann, Sokhoun
    Dul, Sokha
    In, Saraden
    Dussart, Philippe
    Martin, Nicholas J.
    Karlsson, Erik A.
    Garcia-Rivera, Jose A.
    [J]. JOURNAL OF GENERAL VIROLOGY, 2021, 102 (03)
  • [9] Review of COVID-19 Outcomes in Surgical Patients
    Aziz, Hassan
    Filkins, Alexandra
    Kwon, Yong Kyong
    [J]. AMERICAN SURGEON, 2020, 86 (07) : 741 - 745
  • [10] Evaluation of Abbott ID NOW COVID-19 POC test performance characteristics and integration in the regional health network workflows to improve health care delivery
    Babic, N.
    Garner, K. S.
    Hirschhorn, J. W.
    Zebian, R.
    Nolte, F. S.
    [J]. CLINICAL BIOCHEMISTRY, 2023, 117 : 69 - 73